Chugai Releases Disease Awareness Anime about Rheumatoid Arthritis in Multiple Languages Emphasizing Importance of Early Detection/Treatment and Care by Specialists
Chugai Pharmaceutical Co., Ltd. (TOKYO:4519) announced today that it released a disease awareness anime about rheumatoid arthritis dubbed in English and subtitled in Chinese, Korean, French and Spanish, celebrating World Arthritis Day on October 12.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181011005989/en/
(Graphic: Business Wire)
Rheumatoid arthritis is an autoimmune disease that most commonly
develops in women aged from 30 to 59. The number of patients is
estimated to be 0.7 million in Japan and 23 million in the world*. The
disease causes destruction of the joints and bones and deformation of
hands and feet, which may significantly affect daily lives. However,
with recent treatment advances an increasing number of people with the
disease can control joint swelling and pain, as well as continue daily
activities like housekeeping and hobbies, if they visit specialized
medical centers early and receive appropriate treatment.
*Report by
Study Committee on Rheumatoid Arthritis and Allergy; (http://www.mhlw.go.jp/stf/houdou/2r9852000001nfao-att/2r9852000001nfdx.pdf)
and WHO Global Burden of Disease Report (table 7, page 32) 2004; (http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004update_full.pdf)
Chugai has continuously emphasized the importance of early treatment of rheumatoid arthritis and promoted a better understanding through a short film titled “Mother’s Lipstick” (awarded 2016 Cannes Lions Bronze) and a music video titled “With A Wish” released by a singer, Mina Ganaha.
Under the concept of “contribute to the medical community and people’s health around the world by expanding awareness of rheumatoid arthritis among the general public as well as patients and their families,” we have decided to release a disease awareness film by means of anime, one of the icons of Japanese culture. With this movie, we aim to appeal to a broad age range, including the younger generation aged between 10 to 29, about the importance of “early detection”, “early treatment” and “medical care provided by rheumatologists”.
Tatsunoko Production Co., Ltd., a company that has introduced Japan’s leading anime series including “Yatterman” and “The Genie Family” throughout the world, was responsible for character design and production. Ayana Taketatsu, a voice actress who has over one million followers on Twitter, and Kayoko Ohkubo, a comedienne who herself has experienced rheumatoid arthritis, voiced the main characters.
Chugai is continuously committed to promoting disease awareness activities leading to trust and appreciation from all stakeholders including patients, their families, and healthcare professionals, aiming at contributing to the medical community and people’s health around the world.
|
● A Summary of the Rheumatoid Arthritis Awareness Animation |
||
| [Title] | Disease Awareness Anime on Rheumatoid Arthritis, “Magic Glasses” (6 minutes and 55 seconds) | |
| [Released on] | Videos & Advertisements in Chugai Pharmaceutical’s corporate website | |
|
https://www.chugai-pharm.co.jp/english/profile/ad/index.html |
||
| Chugai Pharmaceutical’s YouTube official channel | ||
|
|
||
| [Story] | Nanami and Hikaru have grown up together on an island. They were spending happy and cheerful days. It happened on one of those days when Nanami was a senior in high school. Nanami’s mother started to complain of discomfort of the hands and fingers. Nanami was worried about her mother and took her to a hospital. The symptoms, however, did not improve. Hikaru was determined to become a doctor to help Nanami and her mother suffering from the unexplained symptoms. After becoming a medical student, Hikaru studied hard and encouraged Nanami’s mother to consult a rheumatologist. Nanami was relieved seeing her mother successfully started treatment of rheumatoid arthritis. In fact, Hikaru helped Nanami because he had certain thoughts. | ||
|
[Voice Actors/Actresses (Cast)] |
||
| Character | Cast | |
| Nanami | Ayana Taketatsu / voice actress, singer, and narrator | |
| Hikaru | Miyu Irino / voice actor and singer | |
| Minami | Kayoko Ohkubo / comedienne (Oasiz) | |
| Nozomi | Mizuha Kuraoka / pop star (22/7) | |
About Chugai
Chugai Pharmaceutical is one of Japan’s leading research-based
pharmaceutical companies with strengths in biotechnology products.
Chugai, based in Tokyo, specializes in prescription pharmaceuticals and
is listed on the 1st section of the Tokyo Stock Exchange. As an
important member of the Roche Group, Chugai is actively involved in R&D
activities in Japan and abroad. Specifically, Chugai is working to
develop innovative products which may satisfy the unmet medical needs,
mainly focusing on the oncology area.
In Japan, Chugai’s research
facilities in Gotemba and Kamakura are collaborating to develop new
pharmaceuticals and laboratories in Ukima are conducting research for
technology development for industrial production. Overseas, Chugai
Pharmabody Research based in Singapore is engaged in research focusing
on the generation of novel antibody drugs by utilizing Chugai’s
proprietary innovative antibody engineering technologies. Chugai Pharma
USA and Chugai Pharma Europe are engaged in clinical development
activities in the United States and Europe.
The consolidated
revenue in 2017 of Chugai totalled 534.2 billion yen and the operating
income was 103.2 billion yen (IFRS Core basis).
Additional
information is available on the internet at https://www.chugai-pharm.co.jp/english.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181011005989/en/
Contact information
For Media
Chugai Pharmaceutical Co.,
Ltd.
Media Relations Group, Corporate Communications Dept.,
Tomoko
Shimizu
Tel: +81-3-3273-0881
E-mail: pr@chugai-pharm.co.jp
***
For
European media
Chugai Pharma France SAS
Nathalie Leroy
Tel:
+33-1-56-37-05-21
E-mail: pr@chugai.eu
***
For
Taiwanese media
Chugai Pharma Taiwan Ltd.
Susan Chou
Tel:
+886-2-2715-2000
E-mail: pr@chugai.com.tw
***
For
Investors
Chugai Pharmaceutical Co., Ltd.
Investor
Relations Group, Corporate Communications Dept.,
Toshiya Sasai
Tel:
+81-3-3273-0554
E-mail: ir@chugai-pharm.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Presents New SEQUOIA Study Results Reinforcing BRUKINSA’s Differentiated Profile with or without Venetoclax in Frontline CLL at ASCO 202531.5.2025 15:00:00 EEST | Press release
BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today will present new data from the Arm C and D cohorts of the pivotal, global Phase 3 SEQUOIA trial of BRUKINSA® (zanubrutinib). The findings underscore the strong and consistent efficacy of BRUKINSA across CLL patient types, including high-risk mutation status. These data will be presented in two rapid oral presentations at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL. Data from the Arm D of SEQUOIA demonstrate that treatment with BRUKINSA plus venetoclax has the potential to drive progression-free survival and overall deep and durable responses across the frontline CLL patient spectrum, including patients with high-risk mutational status. The best undetectable minimal residual disease (uMRD) rate in peripheral blood at a sensitivity level 10-4 was 59%. These efficacy responses observed in Arm D, despite the high proportion of high-risk patients enrolled, are in
You Up? Grindr’s “Right Now” Goes Global30.5.2025 16:00:00 EEST | Press release
Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded people without wasting time on mismatched expectations. The response to our initial March launc
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 15:00:00 EEST | Press release
Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative financing approaches to manage the costs of treatment and care. “Despite CAR T-cell therapy being available in the United States for nearly seven years in large B-cell lymphoma, only approximately two out of 10 eligible patients with some advanced blood cancers ever receive CAR T-cell therapy,” said Miguel Perale
Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 12:17:00 EEST | Press release
In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha
FDA Grants De Novo Clearance for Reflow Medical's Spur ® Peripheral Retrievable Stent System30.5.2025 07:08:00 EEST | Press release
Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the company’s Spur Peripheral Retrievable Stent System, a unique clinical solution for the treatment of de novo or restenotic lesions following predilatation in patients with infrapopliteal arterial disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529610368/en/ The first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel complia
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom